Table 3.

Case reports on inflammatory myopathy-ILD patients treated with IVIG

Study	Type	Diseasee	Number of patients	IVIG dosage	Duration of IVIG	Co-medications	Outcome
Suzuki et al [24].	Retrospective study	ILD-PM and ILD-ADMa	5	0.4 g/kg/day for 5 days	1–2 cycles	High doses GCS and CyAb and/or CPMc	Two patients survived > 3 years
Huapaya et al. [23]	Retrospective study	AS-ILD	17	0.4 g/kg/day for 5 days	Once pr. month for a period of 6 month, then increasing intervals between infusions	GCS, MMF, MTX, AZA f	Increasing FVC%, DLCO%d, decreasing prednisone dose
Miyazaki et al [25]	Case report	ADM-ILD	1	0.4 g/kg/day for 5 days	2 cycles	GCS, CyA and CPM	Recovered acute respiratory failure
Murota et al [26]	Case report	DM-ILD	1	0,4 g/kg/day for 5 days	Once pr. month for four month	GCS, CPM and CyA	Full remission
Bakewell et al. [28]	Case report	DM/PM-ILD	1	0.2 g/kg	once pr. month for 3 month	GCS	Clinical remission for >2 years
Diot E et al. [27]	Case report	DM/PM-ILD	1	0,2 g/kg	once pr. month for 3 month	GCS	Increasing VC%, DLCO% and regression in fibrotic changes

a: Amyopathic dermatomyositis

b: Cyclosporine A

c: Cyclophosphamide

d: Percent-predicted forced vital capacity (FVC%) and percent-predicted diffusing capacity of the lung for carbon monoxide (DLCO%)

e: The ILD subtype were not classified in some of the studies

f: The drugs were used as single drugs + IVIG or combination of 2 drugs + IVIG.